Barclays
ARQT icon

Barclays’s Arcutis Biotherapeutics ARQT Stock Holding History

Barclays’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
47,625
+18,660
+64% +$435K ﹤0.01% 2664
2026
Q1 		$682K Sell
28,965
-302,613
-91% -$7.72M ﹤0.01% 2993
2025
Q4 		$9.63M Buy
331,578
+5,610
+2% +$144K ﹤0.01% 1709
2025
Q3 		$6.14M Sell
325,968
-68,073
-17% -$1.07M ﹤0.01% 2035
2025
Q2 		$5.52M Buy
394,041
+199,269
+102% +$2.79M ﹤0.01% 2039
2025
Q1 		$3.05M Sell
194,772
-43,169
-18% -$608K ﹤0.01% 2312
2024
Q4 		$3.31M Sell
237,941
-15,451
-6% -$169K ﹤0.01% 2507
2024
Q3 		$2.36M Buy
253,392
+151,279
+148% +$1.49M ﹤0.01% 2722
2024
Q2 		$950K Buy
102,113
+3,608
+4% +$32.6K ﹤0.01% 2628
2024
Q1 		$976K Sell
98,505
-10,155
-9% -$75.8K ﹤0.01% 3144
2023
Q4 		$351K Sell
108,660
-98,417
-48% -$268K ﹤0.01% 4107
2023
Q3 		$1.1M Sell
207,077
-26,341
-11% -$224K ﹤0.01% 2266
2023
Q2 		$2.22M Sell
233,418
-1,096,647
-82% -$12.2M ﹤0.01% 1821
2023
Q1 		$14.6M Buy
1,330,065
+149,681
+13% +$2.17M 0.01% 987
2022
Q4 		$17.5M Buy
1,180,384
+1,039,547
+738% +$18.2M 0.01% 951
2022
Q3 		$2.69M Buy
140,837
+106,001
+304% +$2.4M ﹤0.01% 1543
2022
Q2 		$742K Sell
34,836
-3,102
-8% -$63.6K ﹤0.01% 2563
2022
Q1 		$730K Buy
+37,938
New +$642K ﹤0.01% 2635

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Barclays's ARQT Position: Q2 2026 in Review

Barclays increased its Arcutis Biotherapeutics (ARQT) stake by 64% in Q2 2026, buying an estimated $435K and bringing the position to 47,625 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

Barclays first reported a position in ARQT in Q1 2022 and has held it in 18 quarters since. The position peaked at $17.5M in Q4 2022. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Barclays held 47,625 shares of Arcutis Biotherapeutics worth $1.25M as of Q2 2026.
  • Barclays bought 18,660 Arcutis Biotherapeutics shares in Q2 2026, an estimated $435K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2664 holding.
  • Barclays first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Arcutis Biotherapeutics position peaked at $17.5M in Q4 2022.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.